HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19 False Advertising Symptoms In US Exceed FTC’s Prognosis For Number, Variety

Executive Summary

FTC Division of Advertising Practices anticipated surge of false ads for consumer health products related to COVID-19 but it didn’t expect quite the number as well as the variety of bogus claims it’s found, says Assistant Director Richard Cleland.

You may also be interested in...



US FDA Testing Finds Consumer Health Market Problems, But It Can’t Test Entire Marketplace

CDER compliance office director Donald Ashley offers a cautionary note to temper expectations for the FDA’s enforcement in the supplement sector. “We continue to warn the public about products very often sold as dietary supplements that contain hidden drugs,” he says.

FDA Left Out Of $80M For Stopping Consumer Product Fraud In Latest US COVID-19 Relief Act

American Rescue Plan Act appropriated $50m to Consumer Product Safety Commission and $30.4m to Federal Trade Commission for COVID-19-related enforcement. Neither agency received funding for pandemic-related enforcement in previous relief packages.

No Hiding Bogus Coronavirus Claims From US Regulators In Social Media Or With Vague Terms

“I don’t know if there’s a misconception that a different set of adverting rules apply to social media," says FTC attorney Christine DeLorme during FDLI conference. The FTC also sees "a lot of attempts at disclaimers. They might say, ‘Of course there’s no cure for COVID, but...’"

Related Content

Topics

UsernamePublicRestriction

Register

RS150440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel